Literature DB >> 16736095

CCL18: a urinary marker of Gaucher cell burden in Gaucher patients.

Rolf G Boot1, Marri Verhoek, Mirjam Langeveld, G Herma Renkema, Carla E M Hollak, Jan J Weening, Wilma E Donker-Koopman, Johanna E Groener, Johannes M F G Aerts.   

Abstract

Glucosylceramide-laden tissue macrophages in Gaucher patients secrete large quantities of chitotriosidase and CC chemokine ligand 18 (CCL18), resulting in markedly increased plasma levels. We have comparatively investigated the occurrence of both parameters in plasma and urine samples of Gaucher patients. Chitotriosidase was high in urine samples of some symptomatic patients, but elevations did not correlate with increased plasma concentrations. Urinary chitotriosidase was particularly high in a patient with severe kidney involvement and local storage cell infiltration. Urinary levels of CCL18 were also highly elevated in samples from Gaucher patients as compared to controls. The median value of the CCL18/creatinine ratio in urine samples of 31 Gaucher patients was 143.3 pg/micromol (range 32-551) and in those of 12 normal subjects was 4.1 pg/micromol (range 1.3-6.8). In sharp contrast to chitotriosidase, increases in the low-molecular-mass chemokine CCL18 in urine and plasma specimens of Gaucher patients correlated well. A correlation was also observed for reductions in urinary and plasma CCL18 following therapy. It is concluded that assessment of urinary CCL18 of Gaucher patients gives insight into the total body burden on Gaucher cells, whereas that of chitotriosidase does not. Urinary chitotriosidase appears rather to be a reflection of renal pathology.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16736095     DOI: 10.1007/s10545-006-0318-8

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  19 in total

1.  Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

Authors:  T Cox; R Lachmann; C Hollak; J Aerts; S van Weely; M Hrebícek; F Platt; T Butters; R Dwek; C Moyses; I Gow; D Elstein; A Zimran
Journal:  Lancet       Date:  2000-04-29       Impact factor: 79.321

2.  Plasma creatinine determination. A new and specific Jaffe reaction method.

Authors:  C Slot
Journal:  Scand J Clin Lab Invest       Date:  1965       Impact factor: 1.713

3.  Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease.

Authors:  Patrick B Deegan; Mary Teresa Moran; Ian McFarlane; J Paul Schofield; Rolf G Boot; Johannes M F G Aerts; Timothy M Cox
Journal:  Blood Cells Mol Dis       Date:  2005 Sep-Oct       Impact factor: 3.039

4.  Identification of a novel acidic mammalian chitinase distinct from chitotriosidase.

Authors:  R G Boot; E F Blommaart; E Swart; K Ghauharali-van der Vlugt; N Bijl; C Moe; A Place; J M Aerts
Journal:  J Biol Chem       Date:  2000-11-20       Impact factor: 5.157

5.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.

Authors:  N W Barton; R O Brady; J M Dambrosia; A M Di Bisceglie; S H Doppelt; S C Hill; H J Mankin; G J Murray; R I Parker; C E Argoff
Journal:  N Engl J Med       Date:  1991-05-23       Impact factor: 91.245

6.  Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages.

Authors:  R G Boot; G H Renkema; A Strijland; A J van Zonneveld; J M Aerts
Journal:  J Biol Chem       Date:  1995-11-03       Impact factor: 5.157

Review 7.  Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring.

Authors:  Antonio Baldellou; Generoso Andria; Pauline E Campbell; Joel Charrow; Ian J Cohen; Gregory A Grabowski; Chris M Harris; Paige Kaplan; Kieran McHugh; Eugen Mengel; Ashok Vellodi
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

8.  The human chitotriosidase gene. Nature of inherited enzyme deficiency.

Authors:  R G Boot; G H Renkema; M Verhoek; A Strijland; J Bliek; T M de Meulemeester; M M Mannens; J M Aerts
Journal:  J Biol Chem       Date:  1998-10-02       Impact factor: 5.157

9.  Comparison of the properties of a soluble form of glucocerebrosidase from human urine with those of the membrane-associated tissue enzyme.

Authors:  J M Aerts; W E Donker-Koopman; M Koot; G J Murray; J A Barranger; J M Tager; A W Schram
Journal:  Biochim Biophys Acta       Date:  1986-12-01

10.  Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

Authors:  C E Hollak; S van Weely; M H van Oers; J M Aerts
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

View more
  10 in total

1.  Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency.

Authors:  Melissa P Wasserstein; Simon A Jones; Handrean Soran; George A Diaz; Natalie Lippa; Beth L Thurberg; Kerry Culm-Merdek; Elias Shamiyeh; Haig Inguilizian; Gerald F Cox; Ana Cristina Puga
Journal:  Mol Genet Metab       Date:  2015-05-30       Impact factor: 4.797

Review 2.  Laboratory and genetic evaluation of Gaucher disease.

Authors:  Olaf A Bodamer; Christina Hung
Journal:  Wien Med Wochenschr       Date:  2010-08-16

3.  Human chitinases and chitinase-like proteins as indicators for inflammation and cancer.

Authors:  Julia Kzhyshkowska; Alexei Gratchev; Sergij Goerdt
Journal:  Biomark Insights       Date:  2007-05-03

Review 4.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Authors:  T M Cox; J M F G Aerts; N Belmatoug; M D Cappellini; S vom Dahl; J Goldblatt; G A Grabowski; C E M Hollak; P Hwu; M Maas; A M Martins; P K Mistry; G M Pastores; A Tylki-Szymanska; J Yee; N Weinreb
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.982

5.  Optimal therapy in Gaucher disease.

Authors:  Ozlem Goker-Alpan
Journal:  Ther Clin Risk Manag       Date:  2010-07-21       Impact factor: 2.423

Review 6.  Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.

Authors:  Johannes M F G Aerts; Wouter W Kallemeijn; Wouter Wegdam; Maria Joao Ferraz; Marielle J van Breemen; Nick Dekker; Gertjan Kramer; Ben J Poorthuis; Johanna E M Groener; Josanne Cox-Brinkman; Saskia M Rombach; Carla E M Hollak; Gabor E Linthorst; Martin D Witte; Henrik Gold; Gijs A van der Marel; Herman S Overkleeft; Rolf G Boot
Journal:  J Inherit Metab Dis       Date:  2011-03-29       Impact factor: 4.982

7.  Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 Gaucher disease patients and mouse models.

Authors:  Gertjan Kramer; Wouter Wegdam; Wilma Donker-Koopman; Roelof Ottenhoff; Paulo Gaspar; Marri Verhoek; Jessica Nelson; Tanit Gabriel; Wouter Kallemeijn; Rolf G Boot; Jon D Laman; Johannes P C Vissers; Timothy Cox; Elena Pavlova; Mary Teresa Moran; Johannes M Aerts; Marco van Eijk
Journal:  FEBS Open Bio       Date:  2016-07-30       Impact factor: 2.693

8.  Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data.

Authors:  Tatiana Raskovalova; Patrick B Deegan; Pramod K Mistry; Elena Pavlova; Ruby Yang; Ari Zimran; Juliette Berger; Céline Bourgne; Bruno Pereira; José Labarère; Marc G Berger
Journal:  Haematologica       Date:  2021-02-01       Impact factor: 9.941

Review 9.  Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.

Authors:  Lunawati L Bennett; Kelsey Turcotte
Journal:  Drug Des Devel Ther       Date:  2015-08-18       Impact factor: 4.162

10.  Gpnmb Is a Potential Marker for the Visceral Pathology in Niemann-Pick Type C Disease.

Authors:  André R A Marques; Tanit L Gabriel; Jan Aten; Cindy P A A van Roomen; Roelof Ottenhoff; Nike Claessen; Pilar Alfonso; Pilar Irún; Pilar Giraldo; Johannes M F G Aerts; Marco van Eijk
Journal:  PLoS One       Date:  2016-01-15       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.